Skills for Health announces Our Health Heroes finalists

By Integrated Care Journal

The finalists for the 2025 Our Health Heroes Awards have been shortlisted.

Our Health Heroes champions the incredible people at the heart of our NHS and is delivered by Skills for Health in partnership with NHS Employers, NHS Shared Business Services, SFJ Awards, NHS Race and Health Observatory and Integrated Care Journal.

After an extensive selection process, 23 finalists have been chosen across nine categories, each recognising the outstanding health heroes of the UK.

The selected finalists will be invited to attend the ceremony held in Central London on 22 May where the gold, silver and bronze award winners will be announced.

The finalists are as follows:

Individual categories

Apprentice of the Year, sponsored by SFJ Awards:

Nasser Mohammed, Service Desk Supervisor/Developer, Leeds and York Partnership NHS Foundation Trust
Tim Muttock, Business Administration Apprentice, Bridgewater Community Healthcare NHS Foundation Trust
Olivia Parsons, Clinic Manager, Beacon House

Healthcare Volunteer of the Year:

Andy Emery, Transport Volunteer, Royal Voluntary Service
David White, Patient Befriender Volunteer, Cardiff and Vale Health Board
Chris Wilson, Volunteer Community First Responder, Yorkshire Ambulance Service NHS Trust

Outstanding Life Contribution, sponsored by NHS Employers:

Caroline Dowsett, Clinical Nurse Specialist, East London Foundation Trust
Vedantee Shiebert, CAMHS Lead Nurse, Central and North West NHS Foundation Trust
Pauline Taylor, Children’s Complex Care Quality Assurance Nurse, Hampshire and Isle of Wight Healthcare NHS Foundation Trust

Operational Support worker of the Year:

Hayley Pedwell, Information Assistant, Macmillan Cancer Care
Brian Taylor, Ambulance Welfare Officer, North East Ambulance Service Unified Solutions
Lois Ward, Communications and Engagement Officer, Chesterfield Royal Hospital

Clinical Support Worker of the Year:

Lynette Cook, Ward Coordinator, Northern Care Alliance NHS Foundation Trust
Sam Desborough, Assistant Practitioner Occupational Therapist, Southwark Council
Sarah Haynes, Healthcare Assistant, Modality Partnership

Team categories

Best Healthcare Workforce Collaboration:

Personalised Independence Programme, Age UK HBW
The What Matters Team, Royal Berkshire NHS Foundation Trust

Dedication to Lifelong Learnt Culture:

Coventry and Warwickshire Training Hub
Patford House Partnership

Equity, Diversity and Inclusion Champion, sponsored by NHS Race and Health Observatory:

Wakefield Hospice
West Midlands Ambulance Service

Digital Innovation, sponsored by NHS Shared Business Services:

Paediatric Virtual Ward Team, Dudley Group of Hospitals NHS Foundation Trust
Recruitment RPA Project Team, Kent Community Health NHS Foundation Trust

Follow #OurHealthHeroes on X (formerly Twitter) and LinkedIn for all the latest updates. To find out more visit: www.skillsforhealth.org.uk/awards

King’s College London becomes first to benefit from two whole-body PET-CT imaging systems

By Integrated Care Journal

As part of the National PET Imaging Platform, King’s College London will support transformational research to improve the calibre of care across the UK, including providing new insights and enhancing the development of drugs and diagnostics for conditions including cancer, cardiovascular and neurological diseases.

King’s College London (Kings) has become the first site in the UK to benefit from two Biograph Vision Quadra systems from Siemens Healthineers, marking a new era of PET-CT. This crucial, non-invasive imaging technique can detect diseases’ early onset, accelerating quality of care for patients while also enabling King’s to conduct innovative radiopharmaceutical, basic science and clinical research.

As part of the UK’s first-of-its-kind National PET Imaging Platform (NPIP), a collaborative initiative bringing together transformational research for clinical discovery, King’s will use the whole-body PET-CT systems for research to improve the calibre of healthcare across the UK.

With PET-CT demand rising nearly 10 per cent annually, this technological upgrade will help King’s meet this demand and significantly expand clinical and research capabilities, positioning King’s at the forefront of global PET-CT research. With higher sensitivity than existing technology, the hospital’s whole-body PET-CT scanners will provide unprecedented insights into anatomy, improving the detection, diagnosis and treatment of complex, multi-organ diseases.

Beyond supporting NPIP, the systems will bolster complex radiopharmaceutical production and tracer development research at King’s (one research tracer production can be used for twice as many scans). Patients will benefit from improved image quality and speed of examination, while a reduction in dose will enhance paediatric diagnostics and treatment.

The UK’s adoption of whole-body PET-CT signifies a major leap forward in medical imaging, promising significant improvements in patient care and research capabilities. Funding for the first installed scanner was secured from the Medical Research Council (MRC), with the system jointly managed by King’s and Imperial College London, scientific co-applicants alongside the King’s team. The second system is financed through a strategic investment by King’s.

Image caption: (L) Peter Kyle – Secretary of State for Science, Innovation and Technology; (R) Professor Sebastien Ourselin, FREng, FMedSci, Assistant Principal (Innovation) at King’s College London visit St.Thomas’ Hospital to launch the NPIP-funded whole-body PET-CT scanner from Siemens Healthineers.

The two whole-body PET-CT systems at King’s are two of four across the UK supporting NPIP, all of which are supplied by Siemens Healthineers. By facilitating access to whole-body PET-CT imaging for clinicians, academics and industry, NPIP is set to accelerate discoveries, leading to more advances for UK researchers and better outcomes for patients. This not only enhances the UK’s clinical infrastructure but also reinforces its position as a global leader in medical technology and research.

Equipped with technical precision that redefines molecular imaging and optimises operational performance, the Biograph Vision Quadra systems from Siemens Healthineers enable near real-time imaging of a patient’s entire body. With an in-depth look at how the body interacts with administered substances, tumours can be characterised allowing for more personalised and precise treatment.

“Whole-body PET-CT has been an area of exciting development and exploration for several years now,” commented Professor Alexander Hammers, Head of the PET Imaging Centre, School of Biomedical Engineering & Imaging Sciences at King’s College London.

“We were very proud to obtain research funding for one whole-body PET-CT system; having a second one on the same site available for clinical use signifies a fundamental milestone in the advancement of nuclear medicine. I am looking forward to enhancing our research activities and our clinical services with two of these innovative scanners.”

“The addition of two new cutting-edge whole-body PET-CT scanners in our PET Centre makes us proud and excited,” added Professor Sebastien Ourselin, FREng, FMedSci, Assistant Principal (Innovation) at King’s College London.

“They will create an incredibly unique setting for the benefit of our patients, and for scaling up research and collaboration endeavours in partnership with Siemens Healthineers.”

Ghada Trotabas, Managing Director of Siemens Healthineers Great Britain and Ireland, stated: “We are honoured to collaborate with King’s College London in their ongoing pursuit to advancing molecular imaging. The installation of two Siemens Healthineers Biograph Vision Quadra systems marks the beginning of a new era in PET-CT imaging, paving the way for groundbreaking advancements in both clinical research and patient care.”

Lead image caption: (From left to right) Giulia Ginami – Strategic Partnerships Manager, Daniel Darian – Collaboration Manager Molecular Imaging, Graham Plant – Head of Diagnostic Imaging at Siemens Healthineers Great Britain & Ireland, Professor Alexander Hammers – Head of the PET Imaging Centre at the School of Biomedical Engineering & Imaging Sciences at King’s College London, Ghada Trotabas – Managing Director of Siemens Healthineers Great Britain & Ireland with one of the two new Biograph Vision Quadra systems at St. Thomas’ Hospital.

This content was kindly supported by Siemens Healthineers.

Reducing misdiagnosis and helping patients back to work

By Mark Thomas

New imaging technology promises to bring affordable, more detailed 3D imaging to care settings around the world, providing faster and more accurate diagnosis and helping patients get the right care.

Scaphoid fractures are notoriously difficult to diagnose, typically presenting among young men following a fall onto an outstretched hand, car accident or contact sport incident. One of eight small bones that make up the ‘carpal bones’ of the wrist, the scaphoid connects two rows of bones: one closer to the forearm and the other closer to the hand. These fractures can present with wrist or thumb pain but not necessarily any visible deformity or significant loss of motion, leading many incidences to be misdiagnosed as wrist sprains.

The scaphoid bone has an avascular blood supply that means, depending on the location and size of the break, there is a real risk of bone death where blood supply is cut off. This leads to a loss of wrist function and dexterity, which can have significant financial implications for those who rely on their flexibility of wrist movement that the scaphoid supports.

This is why MRI and CT images have become the ‘gold standard’ for diagnosis. However, limited resources and long imaging waiting lists mean clinicians across the UK instead rely on X-rays in the first instance. If a scaphoid fracture is suspected, clinicians will typically request four X-ray views, versus two for other wrist injuries, but even that is not a guarantee that the fracture will show as the scaphoid bone can be easily hidden by other carpal bones in a 2D image.

*Traditional 2D film X-ray radiograph showing broken carpal bone (scaphoid fracture)*

It is easy to understand how scaphoid fractures can be easily missed then, particularly in overstretched A&E departments where there may not be sufficient scanner time or radiology cover to diagnose ‘minor injuries’ quickly. Clinical teams usually adopt a conservative approach therefore: Initially treating the injury as if the bone is fractured, with splinting recommended to protect it from further damage, and a follow-up appointment with the fracture clinic in 7-10 days’ time. By this point, if the patient is still experiencing pain, new X-rays will likely reveal initial bone healing more clearly than the original scaphoid break.

It is a sensible approach but one that ultimately causes several problems:

Firstly, where clinicians are concerned about the possibility of a scaphoid fracture but unable to confirm it during the initial visit, splinting the wrist while awaiting further imaging or specialist review means patients can find themselves unable to work unnecessarily, with significant financial implications due to lost earnings.

Scaphoid fractures are usually slow to heal because tiny blood vessels supplying nutrients to the site are often damaged at the time of injury. This means that even though the results of both surgical and non-surgical interventions are very good following diagnosis, both approaches require considerable time in plaster, with knock-on impacts for patients and their dependents, including inability to drive, work and earn normally. Should surgery ultimately be required, it is easy to see how treatment delays of just a couple of weeks can have a real impact on patients’ lives.

Finally, requiring all patients to attend follow-up appointments in fracture clinic has significant resource implications for a healthcare system already under pressure, not least in terms of clinician time and additional imaging requirements.

Improving diagnosis through next-gen imaging

Accepting all of the above, how then can we improve diagnosis for these patients? How can we prevent patients with sprained wrists taking unnecessary time off work, while supporting those with scaphoid fractures to access faster treatment and limit injury-related loss of earnings?

One potential solution lies in a new imaging technology – already proven in the veterinary industry – which promises to bring affordable, more-detailed 3D imaging to the point of care in hospitals and clinics around the world.

This next-generation technology builds on the foundations of digital tomosynthesis (DT) imaging, which is widely used for breast imaging across the NHS. With traditional DT, a conventional X-ray tube moves through a range of angles to derive 3D data – providing better diagnostic information than 2D X-ray but, restricted by its limited depth resolution capabilities, creating difficulties localising some structures and elements.

Adaptix’s unique 3D X-ray technology ‘sweeps’ in two dimensions, enhancing the Z resolution relative to conventional DT. Images are quickly reconstructed – in under 20 seconds – providing slice-by-slice images that can be analysed extremely quickly. This allows for slice thickness adjustments over regions of interest – a particularly important feature when looking for ‘tricky’ fractures, such as those to the scaphoid bone.

The result? A high-resolution 3D image that provides far greater definition and clarity than 2D X-ray techniques, at a cost and radiation dose similar to traditional X-ray. What is more, the compact design of the technology and low-radiation dose, mean it can be brought directly to the point of patient care – reducing time spent moving between hospital departments and allowing clinicians to obtain imaging ‘in clinic’ if needed.

About the author

Mark Thomas, BSc (Hons), PgC, HCPC Reg., Product Manager, Adaptix

Mark spent the first 10 years of his career working as a Radiographer in human healthcare both in the UK and Australia. Later, he focused on CT, managing the Neuro CT Service in Oxford in his final position. In 2008, Mark joined Toshiba/Canon Medical as a CT Specialist, and spent the next 15 years initially providing training, before managing the UK Clinical CT Team. With a strong team Mark drove the adoption of new technologies pushing clinical boundaries, maintaining high clinical integrity and importantly customer satisfaction. Mark’s background gives him real clarity on the future and opportunity for inclusion of Digital Tomosynthesis Imaging in a modern, forward thinking Imaging Service.

Data solutions to solve the South West’s patient discharge crisis

By Professor Christos Vasilakis and Dr Zehra Onen Dumlu

Professor Christos Vasilakis, Founding Director of the Centre for Healthcare Innovation and Improvement – CHI²) and Dr. Zehra Onen Dumlu from the University of Bath discuss the IPACS project – a collaborative, data-driven approach to improving patient flow.

Delayed discharges, often known as ‘bed blocking’, is a serious operational challenge for NHS managers across the country. According to NHS England data, in February 2024 there were between 13,200 and 14,200 patients remaining in hospital each day who did not meet the criteria to stay. This accounts for more than one in eight general and acute beds in England.

While patients are deemed medically fit for discharge, they remain in hospital due to complexities in arranging necessary social care or community nursing support for a safe transition. The knock-on effects are significant, placing immense strain on acute bed capacity and negatively impacting patient flow and their experience.

The IPACS project: A collaborative, data-driven approach

To address the issue, the Improving Patient Flow between Acute, Community, and Social Care (IPACS) project was launched in 2020. This significant three-year initiative received funding from Health Data Research UK (HDRUK), an independent charity focused on using health data research to address major healthcare challenges.

IPACS brought together a diverse team, combining academic expertise with frontline NHS operational knowledge. Collaborators included the University of Bath, the University of Exeter Medical School, and significantly, the Bristol, North Somerset, and South Gloucestershire (BNSSG) Integrated Care Board (ICB).

The goal of the project was to develop an open-source computer simulation model capable of analysing the complex dynamics of patient flow. This tool would offer a potential blueprint for healthcare organisations nationwide grappling with delayed discharge pressures.

Central to the project was the application of Operational Research (OR) techniques – using advanced analytical models to dissect and solve complex systemic problems. Several team members brought extensive OR experience, with affiliations to The Operational Research Society, demonstrating the project’s robust methodological foundation aimed at enhancing healthcare efficiency.

A multidisciplinary team driving innovation

The success of IPACS hinged on its multidisciplinary collaboration. BNSSG ICB’s Head of Modelling and Analytics, Dr Richard Wood, and University of Bath Research Fellow Dr Paul Forte provided essential insights into real-world healthcare operations and ensured the project outputs were relevant and accessible to NHS decision-makers.

Academic leadership came from Professor Christos Vasilakis (founding director of the Centre for Healthcare Innovation and Improvement – CHI²) and Dr Zehra Onen Dumlu at the University of Bath, working alongside Professor Martin Pitt and Dr Alison Harper from the University of Exeter Medical School. This combined team undertook the intricate task of designing, developing, and validating the simulation framework.

Focusing on the critical ‘Discharge to Assess’ service

A key focus for the IPACS project was the transition of patients from acute settings into community care, specifically via the ‘Discharge to Assess’ (D2A) service. Optimising this service is key to improving hospital throughput. The project modelled the three core D2A pathways:

Pathway 1 (P1): Enabling patients to return home with domiciliary support.
Pathway 2 (P2): Providing bed-based rehabilitation for those needing more intensive recovery support post-discharge.
Pathway 3 (P3): Catering for complex care assessments, frequently leading to long-term care placements.

The IPACS model aimed to help optimise capacity planning and resource allocation across these vital pathways.

The BNSSG region: A relevant testing ground

The Bristol, North Somerset, and South Gloucestershire (BNSSG) region, serving approximately one million people, served as a practical case study. Its demographic mix and blend of urban and rural environments reflect challenges common across the NHS. The region’s D2A pathways were experiencing significant pressure, with high occupancy and discharge delays, providing a rich, real-world dataset and demonstrating the urgent need for the solutions IPACS explored.

Operational Research and simulation modelling in practice

Professor Vasilakis and Dr Wood pinpointed the core management challenge: the complex interdependencies between acute, community, and social care services. Bottlenecks in community and social care inevitably impact upstream services, contributing to emergency department pressures and ambulance handover delays.

The IPACS team used real-time data on patient occupancy and discharge delays to build their model. This allowed them to establish baseline performance and, critically, to run “what if” scenarios, varying parameters like length of stay and arrival rates to understand potential impacts of service changes.

Computer simulation modelling, a cornerstone of OR, was central to this. The model allowed the team to:

Simulate patient journeys through the D2A pathways in detail.
Test potential interventions virtually to assess their likely impact on flow and delays.
Analyse how best to allocate resources to mitigate discharge delays.
Account for time-varying demand patterns.

Built using the open-source ‘R’ programming language, the model prioritised accessibility and transparency.

Demonstrating real-world impact and future potential

The IPACS model provided valuable quantitative insights. Outputs clearly demonstrated the potential benefits of achieving target pathway splits and reducing lengths of stay within the D2A service. Significantly, estimates generated by the model were used to support a £13 million business case for enhancing the local D2A system – highlighting the project’s tangible value in informing strategic investment decisions.

The team acknowledged the model does have some limitations. It doesn’t yet capture every element of discharge, such as specific social care inputs, palliative care routes, or detailed post-D2A placement dynamics. Data completeness also needs some ongoing attention. Future work could involve expanding the model’s scope to incorporate social care elements more deeply, analyse the impact of acute capacity constraints, optimise home-based care models, and potentially develop faster analytical tools.

The ongoing challenge and strategic steps forward

Tackling delayed discharge requires effective strategies, and the IPACS project highlights the value of OR. Using OR methods such as simulation modelling allows NHS managers to better understand complex discharge pathways, evaluate potential solutions before implementation, and make more informed, evidence-based decisions about resource allocation to improve patient flow and reduce delays.

*Dr Zehra Onen Dumlu, Assistant Professor, University of Bath*

*Professor Christos Vasilakis, Founding Director, Centre for Healthcare Innovation and Improvement – CHI²*

Accelerating NHS net zero goals through medicine carbon footprinting

By Samantha Semmeling

With medicines accounting for a quarter of the NHS carbon footprint, Nazneen Rahman, Founder of YewMaker and co-creator of MCF Classifier, explains how AI-driven medicine carbon emissions data can support practical, scalable strategies that align clinical excellence and environmental stewardship.

The climate crisis is resulting in acute and chronic health challenges, which are putting pressure on global health systems. In turn, the healthcare sector is estimated to account for 5 per cent of global greenhouse gas emissions. This places a unique responsibility on the sector to both manage these impacts and reduce its contribution to climate change.

More than 20 countries have committed to delivering net zero health systems. In the UK, the Health and Care Act 2022 embedded the commitment for the NHS to become net zero by 2045 into legislation, making it the first health system worldwide to do so.

Progress on sustainable medicines

Medicines make a sizeable contribution to the NHS’ carbon footprint (an estimated 25 per cent), so a comprehensive strategy to reduce medicines-related emissions is necessary for the NHS to reach its net zero goals.

The NHS is already making headway. Green plan guidance now recommends that systems and trusts use lower carbon inhalers and anaesthetics, which has already seen successful uptake.

However, of the 25 per cent attributed to medicines, inhalers and anaesthetics only account for 5 per cent. The remaining 20 per cent comes from the manufacture and supply of the billions of medicines prescribed across the NHS every year.

Progress on reducing these emissions has been hindered by a lack of accessible product-level emissions data. Manufacturer data is rarely made available and is not standardised, making it difficult to use as a baseline for carbon reduction strategies.

MCF Classifier – Medicine emissions data at scale

YewMaker creates science-based solutions to help make healthcare more sustainable. Chief Executive Officer, Nazneen Rahman and Chief Technology Officer, Haroon Taylor saw an opportunity to harness industry standards in green chemistry, using AI and data science to develop a standardised methodology for calculating the carbon footprint of individual medicines. The resulting technology suite, MCF Classifier (MCF = Medicine Carbon Footprint), provides data and tools that enable the manufacture, supply, emissions, procurement, and prescription of medicines to be carbon-informed.

“We developed MCF Classifier to make medicine emissions visible, consistent, and usable,” says Nazneen. “Without that foundation, it’s difficult for anyone – whether in procurement, policy or practice – to take meaningful action.”

The methodology behind MCF Classifier has been peer-reviewed and published, bringing transparency and credibility to an area where data has been limited and inconsistent. Research using MCF Classifier has shown wide variation in medicine carbon footprints across all therapeutic areas, highlighting significant opportunities for carbon-informed decisions in procurement, supply chain planning, and prescribing.

YewMaker is now building MCF Classifier tools and products to drive awareness and action. MCF Formulary, supported by NHS funding, provides standardised per-dose carbon ratings for thousands of medicines through a free, user-friendly web portal. It allows healthcare practitioners to explore the relative carbon impact of medicines and integrate sustainability into medicine optimisation strategies.

For manufacturers and suppliers, YewMaker uses MCF Classifier to deliver a range of data products and services, including product carbon footprint reports, large-scale emissions analyses, portfolio-wide carbon assessments, and therapy emission comparisons. These support organisations to understand and mitigate the carbon impact of their medicines and to meet reporting requirements.

Advancing NHS net zero goals

The NHS has committed to reach net zero by 2045 for emissions influenced through the procurement of goods and services, including medicines. To help suppliers align with this goal, the NHS has developed a roadmap outlining key milestones. By 2027, all suppliers are required to publish a Carbon Reduction Plan, and by 2028, they must provide carbon footprint data for individual products.

Reducing supply chain carbon emissions will be essential. However, delivering on these targets will require practical and proportionate approaches. Nazneen highlights the importance of ensuring that new expectations, such as product-level carbon reporting, are introduced in ways that support, rather than disrupt, medicines supply. Tools like MCF Classifier can help by providing suppliers with accessible, consistent data that supports engagement without creating unnecessary complexity or burden.

Nazneen emphasises that carbon data should not be seen as a compliance exercise, but as a resource to support informed, balanced decisions. As understanding of product-level emissions improves, suppliers will be better placed to identify areas for reduction while maintaining stability and quality across the supply chain.

Improving the sustainability of the medicines supply chain will require coordinated efforts among multiple stakeholders. Collaboration at the organisational, sectoral, national and global levels will be essential in creating a supply chain that is not only resilient and cost-effective but also environmentally responsible.

By embedding carbon considerations into decision-making, the NHS can continue to lead in aligning clinical excellence with environmental sustainability and take meaningful steps towards delivering a net zero health system.

Further information

Dr Nazneen Rahman is CEO and Founder at YewMaker, a purpose-driven business building science-based sustainable healthcare solutions, and the Executive Director of the Sustainable Medicines Partnership action collaborative.

If you are interested in this topic or PPP’s pharmacy and medicines work more broadly, please contact Samantha Semmeling, Policy and Programmes Manager, Public Policy Projects (samantha.semmeling@publicpolicyprojects.com).

Benefits of single-handed care highlighted at new qualification launch

By Integrated Care Journal

Level 2 Proportionate Single-Handed Care qualification formalises single-handed care principles into Ofqual regulated training for the first time. The qualification counters the misconception that it is unlawful to provide moving and handling care activities with less than two handlers.

Leading figures in the social care sector, including representatives from Care England, Department of Health and Social Care and the NHS, came together at the House of Lords on Wednesday 2 April for the launch of the Level 2 Proportionate Single-Handed Care Qualification, developed by the Royal Society for the Prevention of Accidents (RoSPA) and A1 Risk Solutions Ltd.

The event was hosted by RoSPA Vice President Baroness Watkins of Tavistock, who reflected on how her own background in nursing has demonstrated both the importance of greater recognition of care workers’ skills, and the need for improved pathways to developing them.

Watkins said: “Working as a nurse myself gave me firsthand experience of how care workers are the backbone of our health and social care system, delivering care, kindness and support to hundreds of thousands of people on a daily basis. Despite the increasing demand for social care, with requests for support from new clients reaching over two million in 2023-24, the vital contributions of care workers often go unrecognised.

“The qualification not only benefits individual care workers by enhancing their skills and job satisfaction but also promotes privacy, independence, and flexibility for service users. It ensures that care is delivered effectively, safely, and with dignity, without compromising the health and wellbeing of either party.

“By investing in our care workers, we are investing in the future of our health and social care system.”

In her keynote address, RoSPA Chief Executive Rebecca Hickman explained how the new qualification builds on the charity’s commitment to ensuring the highest health and safety standards across the whole of society.

Rebecca Hickman said: “The Level 2 Proportionate Single-Handed Care Qualification is a new addition to RoSPA’s suite of highly respected training qualifications for the social care sector, such as our Level 2 Adult Social Care Certificate and our Level 3 Award for Safer People Handling Trainers.

“Developed in collaboration with key partners and supported by sector leaders, this qualification is designed to enhance the skills and knowledge of professionals, empowering them to deliver safer and more effective care.

“This qualification is based on the latest evidence and best practice. By setting high standards, recognising excellence, and delivering comprehensive training, RoSPA continues to lead the agenda in making society safer for everyone.”

The Level 2 Proportionate Single-Handed Care qualification is the first time the principles of single-handed care has been formalised into an Ofqual regulated training programme.

Proportionate/single-handed care encourages a more personalised approach to supporting a person’s moving and handling requirements. This ensures the person receives the optimum amount of care and support in the correct environment. By enabling individuals to do as much for themselves as possible, proportionate/single-handed care reduces the likelihood of them becoming deconditioned and being readmitted to hospital or admitted to long-term care. This also has the benefit of freeing up capacity across the wider health and social care system.

Alongside training staff in areas such as risk assessment and the practical delivery of safe moving and handling, the qualification counters the misconception that it is unlawful to provide moving and handling care activities with less than two handlers. Care should not be over prescribed and should be proportionate to the needs of each person to ensure that it does not foster dependency.

Find out more about the Level 2 Proportionate Single-Handed Care qualification.

Acute Care, Community Care, Featured, News, Secondary Care April 10, 2025

Embedding social prescribing in secondary care: A toolkit from Barts Health

By Gabriel Blaazer

Barts Health NHS Trust and its partner organisation, Transformation Partners in Health and Care, have released a toolkit detailing their pioneering work embedding social prescribing in secondary care and specialist acute pathways. The toolkit aims to help providers address unmet social needs, improve patient outcomes and reduce demand on acute services, shaping a holistic, prevention-focused model for the future NHS.

Social prescribing attempts to address the social determinants of health. These are the non-medical factors influencing 84 per cent of a person’s total health, with clinical care impacting the remainder. Social determinants of heath include income security and employment, education, housing and food insecurity, or social isolation.

Introduced in England in 2018, it typically involves signposting or referrals to appropriate services, but can also include emotional and mental health support for people experiencing social isolation or low-level mental health issues. Social prescribing is a holistic, person-centred and preventative approach and as such, is a key enabler of the government’s efforts to shift more care into the community and bolster prevention initiatives.

Emerging evidence suggests that social prescribing is an effective, yet low-cost, preventative intervention. However, its implementation has been more frequent in primary and community care, compared to secondary care. In 2023, Barts Health NHS Trust (Barts Health), one of Europe’s largest acute healthcare providers, started implementing social prescribing across multiple pathways, using different integration models to support a whole system approach to prevention and personalised care.

These services, delivered by social prescribers in collaboration with clinical and wider multi-disciplinary teams, support residents with their social needs while aiming to reduce demand on high-pressure services, including cardiovascular (CVD), renal, emergency care, and children and young people’s (CYP) services.

Encouraged by positive outcome data, the Trust and its partner organisation, Transformation Partners in Health and Care (TPHC), have developed a toolkit to help secondary care services embed social prescribing, public health and other community-led prevention initiatives within their specialties and pathways. The toolkit serves as a practical guide and checklist for secondary care providers looking to implement social prescribing and explore integrated, whole-system approaches to prevention.

Addressing unmet needs

While NHS England has established a standard model for embedding social prescribing, this has primarily focused on integration within primary care. In 2023, Barts Hospital’s Endovascular Team, led by Vascular Surgeon Dr Tara Mastracci, identified a high prevalence of unmet social need among patients in the hospital’s cardiovascular pathway – a well-evidenced correlation. Given that CVD disproportionately affects socially deprived populations, Dr Mastracci theorised that integrating social prescribing could benefit those at highest risk, simultaneously alleviating pressure on the pathway and improving patient outcomes.

A key data point supporting the use of social prescribing in secondary care was the gender split between typical users of social prescribing services and those presenting with acute cardiovascular issues. While 84 per cent of patients within cardiovascular pathways were men, 60 per cent of social prescribing users were women. Research has shown that women consult primary care services 32 per cent more frequently than men, suggesting that secondary care could play a central role in engaging men, who might otherwise remain underserved by traditional social prescribing models.

“Overall, we have found that we encounter a different group of patients compared with those who access social prescribing in primary care.”

Dr Tara Mastracci, Endovascular Lead for Complex Aortic Surgery, Barts Health

This reinforced Dr Mastracci’s belief in the merit of social prescribing within secondary care – clearly, more effort was needed to engage men, particularly for CVD patients who could benefit from greater social support.

Building a collaborative approach

Several specialties within the Trust had also identified unmet social needs as a key driver of service demand, and had begun implementing social prescribing programmes within their pathways. However, these initiatives were siloed, staff-led and reliant on temporary funding or fixed grants. To enhance collaboration and sustainability, Dr Mastracci established a multidisciplinary network of staff across primary and secondary care to drive a more integrated and formalised approach.

Finding limited guidance on implementing social prescribing within secondary care, Dr Mastracci’s CVD team set out to develop a replicable model for implementing it as part of secondary care pathways. Keen to apply the same rigorous standards as with a medical intervention, the team partnered with health economists at the University of East London. They incorporated EQ-5D instruments and QALY (quality-adjusted life years) metrics to evaluate the potential impact of social prescribing on both patients and the wider health and care system.

Recognising the need for greater institutional knowledge and community expertise, the team also partnered with the Bromley by Bow Centre (now Bromley by Bow Health), a leading VCSFE (Voluntary, Community, Social, and Faith Enterprise) community health organisation. This collaboration led to the embedding of a social prescriber within the hospital’s heart attack pathway, screening patients entering the pathway for financial or other social needs.

Implementation and outcomes

Once identified, social prescribers provided patients with six to eight support sessions, connecting them to local services and community groups tailored to their specific social needs. Beyond financial deprivation, patients received support for needs including housing, talking therapies, and healthy lifestyle support such as smoking and alcohol cessation, or physical activity and weight management – all of which play key roles in determining a person’s risk of developing CVD-related conditions.

The social prescribers were drawn from diverse backgrounds and communities, to work in collaboration with clinicians and consultants from secondary care, patient advocate groups, VSCFE organisations and others. This multidisciplinary approach facilitated a holistic and patient-centred approach. The experiences and lessons from creating the CVD social prescribing pathway were later used to inform other specialties as they implemented similar services within their pathways.

“We believe strongly in the importance of ‘place’ and thus many of our social prescribers meet patients in the community where they live to engage and provide support.”

Dr Tara Mastracci, Endovascular Lead for Complex Aortic Surgery, Barts Health

Dr Mastracci acknowledges that it will take years to fully assess the impact of Barts Health’s social prescribing programmes. “We know these target groups are admitted at higher rates than their peers,” Dr Mastracci told ICJ, “but it will take years to evaluate the long-term effects.”

Despite this, early results have been promising, notably within children and young people’s (CYP) diabetes services. Led by Dr Myuri Moorthy, Diabetes Consultant and Clinical Lead for Young Adult Diabetes (YAD) at Barts Health, clinicians in the pathway had noticed a concerning increase in non-adherence to self-management protocols, often linked to concurrent financial and psychosocial issues. The service also saw high numbers of patients not attending appointments (DNAs), largely due to distress, burnout, and the intense mental health toll associated with diabetes.

Poor diabetes self-management is well known to increase the likelihood of complications. This prompted the diabetes team to adopt a co-designed and personalised model, including a multi-disciplinary team of social prescribers, youth workers and a psychologist. The aim of the YAD Social Prescribing Service was to improve patient engagement, reduce DNAs and maximise the impact of each clinical appointment.

Together with service users, the team co-developed a series of interventions, including monthly peer support meetings, a WhatsApp group and a ‘walk and talk’ group, securing funding from NHSE for two and a half years. During this time, the team successfully:

Reduced the DNA rate across the Trust from 39 per cent to 12.5 per cent
Cut diabetes-related hospital admissions of CYP by 36 per cent across all Barts sites
Generated financial savings of an estimated £62,500 per year across the Trust

More outcomes from the prevention initiatives across Barts Health, including economic and demand savings, stronger integrated community networks and improved outcomes and patient experience, can be found on pages 26-30 of the toolkit.

Gaining leadership buy-in

As with many prevention-based interventions, the impact of social prescribing on health and care systems can take years to fully assess. In its paper on integrated neighbourhood teams (within which social prescribers typically sit), The National Association of Primary Care suggests that “savings will be non-cash releasing, but this is not as issue as what is required is capacity and health improvement.” However, this long-term approach does not easily align with NHS funding cycles, which typically require demonstrable return on investment within 12 months.

Currently, all of Barts Health’s social prescribing pathways are funded individually, on an ad hoc basis. The CVD project, for example, was initially funded by NHSE, but is now supported by Barts Charity. To move towards trust-wide funding, TPHC’s Secondary Care Project Manager, Mollie McCormick, emphasises the need to develop:

Robust databases and coding frameworks to accurately track interventions and outcomes over time
Qualitative data collection from patients benefiting from social prescribing, with an emphasis on reduced need for healthcare services and thus cost savings

Bridging the gap between identifying social needs that drive demand and demonstrating short-term cost savings remains a challenge. However, securing the backing and support of senior clinical leadership is critical in building the case for long-term investment.

For social prescribing initiatives to gain trust-wide funding in future, structural changes are needed to prioritise long-term prevention and strengthen outcomes-based commissioning. Different approaches could involve integrated care systems incentivising prevention by:

Setting realistic and appropriate prevention targets for NHS trusts to influence commissioning decisions towards the implementation of personalised care and prevention initiatives
Introducing penalties for avoidable readmissions

These targets could be assessed by monitoring readmission rates for specific condition cohorts or high-demand service areas, ensuring a measurable focus on prevention.

The toolkit: Embedding and Connecting Prevention in Specialist Pathways

Barts Health and TPHC have now published their toolkit, Embedding and Connecting Prevention in Specialist Pathways. Along with background information on the benefits of social prescribing and community-led prevention, the toolkit addresses some of the key systemic barriers that Barts Health encountered while implementing initiatives across various pathways and specialties.

Using case studies and the first-hand insights from patients, social prescribers and clinicians, the toolkit offers practical guidance for those looking to implement community-led prevention approaches, such as social prescribing, in secondary care. It also provides an overview of key Barts Health prevention networks and identifies the leaders driving this work across the Trust. The toolkit offers a valuable resource for anyone working in an acute setting wanting to embed social prescribing into their services or to prioritise the prevention of ill health in NHS Trusts across London and nationally.

Social prescribing: A key enabler of NHS prevention goals

Emerging evidence strongly supports social prescribing as a cost-effective intervention for tackling the wider determinants of health and addressing the often-overlapping health inequalities that contribute to high demand for NHS services.

Further, as the government seeks to move more care from hospitals to communities as part of its ‘three shifts’, initiatives like social prescribing will be increasingly vital. By reducing pressure on secondary care services and helping local systems meet their financial and operational goals, social prescribing plays a crucial role in shaping the future of preventative, person-centred and sustainable healthcare.

Special thanks to Dr Tara Mastracci, Endovascular Lead for Complex Aortic Surgery at Barts Health, and Mollie McCormick, Secondary Care Project Manager at Transformation Partners in Health and Care, for their time and input in developing this article.

All news